- Home
- GHM vs ARVN Comparison
GHM vs ARVN Comparison
Compare GHM & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHM
- ARVN
- Stock Information
- Founded
- GHM 1936
- ARVN 2015
- Country
- GHM United States
- ARVN United States
- Employees
- GHM N/A
- ARVN N/A
- Industry
- GHM Industrial Machinery/Components
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- GHM Industrials
- ARVN Health Care
- Exchange
- GHM Nasdaq
- ARVN Nasdaq
- Market Cap
- GHM 409.5M
- ARVN 456.2M
- IPO Year
- GHM N/A
- ARVN 2018
- Fundamental
- Price
- GHM $50.90
- ARVN $7.70
- Analyst Decision
- GHM Buy
- ARVN Buy
- Analyst Count
- GHM 2
- ARVN 21
- Target Price
- GHM $45.00
- ARVN $20.53
- AVG Volume (30 Days)
- GHM 118.0K
- ARVN 2.1M
- Earning Date
- GHM 06-09-2025
- ARVN 07-29-2025
- Dividend Yield
- GHM N/A
- ARVN N/A
- EPS Growth
- GHM 164.29
- ARVN N/A
- EPS
- GHM 1.11
- ARVN N/A
- Revenue
- GHM $209,896,000.00
- ARVN $426,900,000.00
- Revenue This Year
- GHM $10.67
- ARVN $4.26
- Revenue Next Year
- GHM $9.35
- ARVN N/A
- P/E Ratio
- GHM $45.56
- ARVN N/A
- Revenue Growth
- GHM 13.13
- ARVN 498.74
- 52 Week Low
- GHM $24.78
- ARVN $5.90
- 52 Week High
- GHM $52.00
- ARVN $34.11
- Technical
- Relative Strength Index (RSI)
- GHM 76.38
- ARVN 58.03
- Support Level
- GHM $45.00
- ARVN $7.09
- Resistance Level
- GHM $51.28
- ARVN $7.89
- Average True Range (ATR)
- GHM 1.75
- ARVN 0.40
- MACD
- GHM 0.17
- ARVN 0.06
- Stochastic Oscillator
- GHM 94.74
- ARVN 63.03
About GHM Graham Corporation
Graham Corporation designs and manufactures mission-critical fluid, power, heat transfer, and vacuum technologies for the defense, space, energy, and process industries. The company also services and sells spare parts for its equipment. It designs and manufactures custom-engineered vacuum, heat transfer, cryogenic pump and turbomachinery technologies.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.